47.88
0.79%
-0.375
After Hours:
47.84
-0.045
-0.09%
Overview
News
Price History
Option Chain
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol-Myers Squibb Co. stock is currently priced at $47.88, with a 24-hour trading volume of 9.95M.
It has seen a -0.79% decreased in the last 24 hours and a -8.52% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $48.37 pivot point. If it approaches the $47.77 support level, significant changes may occur.
Bristol-Myers Squibb Co. Stock (BMY) Financials Data
Bristol-Myers Squibb Co. (BMY) Revenue 2024
BMY reported a revenue (TTM) of $45.01 billion for the quarter ending December 31, 2023, a -2.50% decline year-over-year.
Bristol-Myers Squibb Co. (BMY) Net Income 2024
BMY net income (TTM) was $8.03 billion for the quarter ending December 31, 2023, a +26.84% increase year-over-year.
Bristol-Myers Squibb Co. (BMY) Cash Flow 2024
BMY recorded a free cash flow (TTM) of $12.65 billion for the quarter ending December 31, 2023, a +5.88% increase year-over-year.
Bristol-Myers Squibb Co. (BMY) Earnings per Share 2024
BMY earnings per share (TTM) was $3.86 for the quarter ending December 31, 2023, a +30.85% growth year-over-year.
Bristol-Myers Squibb Co. Stock (BMY) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Shanahan Karin | EVP, Glob. Prod. Dev. & Supply |
Apr 01 '24 |
Option Exercise |
0.00 |
3,306 |
0 |
6,532 |
Lenkowsky Adam | EVP, Chief Commercial Officer |
Mar 10 '24 |
Option Exercise |
0.00 |
15,016 |
0 |
13,859 |
LEUNG SANDRA | EVP, General Counsel |
Mar 10 '24 |
Option Exercise |
0.00 |
46,784 |
0 |
371,312 |
Plenge Robert M | EVP, Chief Research Officer |
Mar 10 '24 |
Option Exercise |
0.00 |
9,143 |
0 |
15,182 |
Poole Ahn Amanda | EVP, Chief Human Resources |
Mar 10 '24 |
Option Exercise |
0.00 |
5,458 |
0 |
4,841 |
Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. |
Mar 10 '24 |
Option Exercise |
0.00 |
38,388 |
0 |
80,256 |
Holzer Phil M | SVP and Controller |
Mar 10 '24 |
Option Exercise |
0.00 |
5,520 |
0 |
14,916 |
Hoch Lynelle | President, Cell Therapy Org. |
Mar 10 '24 |
Option Exercise |
0.00 |
4,351 |
0 |
3,781 |
Gallman Cari | EVP, Corporate Affairs |
Mar 10 '24 |
Option Exercise |
0.00 |
2,761 |
0 |
2,655 |
BOERNER CHRISTOPHER S. | Chief Executive Officer |
Mar 10 '24 |
Option Exercise |
0.00 |
54,638 |
0 |
129,769 |
Bristol-Myers Squibb Co. Stock (BMY) Latest News
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
Zacks Investment Research
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
The Motley Fool
Pfizer's Doldrums, Just A Bad Case Of COVID-19?
Seeking Alpha
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
Zacks Investment Research
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
The Motley Fool
Better Growth Play: Merck or The Vanguard Growth Index Fund?
The Motley Fool
About Bristol-Myers Squibb Co.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The company has collaboration agreements with Nektar Therapeutics; Illumina, Inc.; Janssen Pharmaceuticals, Inc.; Advantagene, Inc.; Compugen Ltd.; Infinity Pharmaceuticals, Inc.; and Tsinghua University, as well as a research partnership with Sirenas. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Cap:
|
Volume (24h):